246 related articles for article (PubMed ID: 19041355)
1. Some guidelines for determining foot-and-mouth disease vaccine strain matching by serology.
Mattion N; Goris N; Willems T; Robiolo B; Maradei E; Beascoechea CP; Perez A; Smitsaart E; Fondevila N; Palma E; De Clercq K; La Torre J
Vaccine; 2009 Jan; 27(5):741-7. PubMed ID: 19041355
[TBL] [Abstract][Full Text] [Related]
2. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
Maradei E; La Torre J; Robiolo B; Esteves J; Seki C; Pedemonte A; Iglesias M; D'Aloia R; Mattion N
Vaccine; 2008 Dec; 26(51):6577-86. PubMed ID: 18835312
[TBL] [Abstract][Full Text] [Related]
3. Confidence in indirect assessment of foot-and-mouth disease vaccine potency and vaccine matching carried out by liquid phase ELISA and virus neutralization tests.
Robiolo B; La Torre J; Maradei E; Beascoechea CP; Perez A; Seki C; Smitsaart E; Fondevila N; Palma E; Goris N; De Clercq K; Mattion N
Vaccine; 2010 Aug; 28(38):6235-41. PubMed ID: 20643090
[TBL] [Abstract][Full Text] [Related]
4. Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.
Goris N; Maradei E; D'Aloia R; Fondevila N; Mattion N; Perez A; Smitsaart E; Nauwynck HJ; La Torre J; Palma E; De Clercq K
Vaccine; 2008 Jun; 26(27-28):3432-7. PubMed ID: 18499310
[TBL] [Abstract][Full Text] [Related]
5. Selection of foot and mouth disease vaccine strains--a review.
Paton DJ; Valarcher JF; Bergmann I; Matlho OG; Zakharov VM; Palma EL; Thomson GR
Rev Sci Tech; 2005 Dec; 24(3):981-93. PubMed ID: 16642769
[TBL] [Abstract][Full Text] [Related]
6. Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle.
Lavoria MÁ; Di-Giacomo S; Bucafusco D; Franco-Mahecha OL; Pérez-Filgueira DM; Capozzo AV
Vaccine; 2012 Nov; 30(48):6845-50. PubMed ID: 23000129
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the immune response to FMDV structural and non-structural proteins in cattle in Argentina by the combined use of liquid phase and 3ABC-ELISA tests.
Robiolo B; Seki C; Fondevilla N; Grigera P; Scodeller E; Periolo O; La Torre J; Mattion N
Vaccine; 2006 Feb; 24(7):997-1008. PubMed ID: 16171905
[TBL] [Abstract][Full Text] [Related]
8. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease.
Mattion N; König G; Seki C; Smitsaart E; Maradei E; Robiolo B; Duffy S; León E; Piccone M; Sadir A; Bottini R; Cosentino B; Falczuk A; Maresca R; Periolo O; Bellinzoni R; Espinoza A; Torre JL; Palma EL
Vaccine; 2004 Oct; 22(31-32):4149-62. PubMed ID: 15474705
[TBL] [Abstract][Full Text] [Related]
9. Quantitative single serum-dilution liquid phase competitive blocking ELISA for the assessment of herd immunity and expected protection against foot-and-mouth disease virus in vaccinated cattle.
Robiolo B; La Torre J; Duffy S; Leon E; Seki C; Torres A; Mattion N
J Virol Methods; 2010 Jun; 166(1-2):21-7. PubMed ID: 20170683
[TBL] [Abstract][Full Text] [Related]
10. Antigenic and genetic analyses of foot-and-mouth disease virus type A isolates for selection of candidate vaccine strain reveals emergence of a variant virus that is responsible for most recent outbreaks in India.
Jangra RK; Tosh C; Sanyal A; Hemadri D; Bandyopadhyay SK
Virus Res; 2005 Sep; 112(1-2):52-9. PubMed ID: 16022900
[TBL] [Abstract][Full Text] [Related]
11. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
Brehm KE; Kumar N; Thulke HH; Haas B
Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of traditional and novel serology tests for predicting cross-protection in foot-and-mouth disease vaccinated cattle.
Brito BP; Perez AM; Capozzo AV
Vaccine; 2014 Jan; 32(4):433-6. PubMed ID: 24342253
[TBL] [Abstract][Full Text] [Related]
13. Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies.
Seki C; Robiolo B; Periolo O; Iglesias M; D'Antuono A; Maradei E; Barros V; La Torre J; Mattion N
Vet Microbiol; 2009 Jan; 133(3):239-51. PubMed ID: 18774662
[TBL] [Abstract][Full Text] [Related]
14. Assessment of suitability of two serotype A candidate vaccine strains for inclusion in FMD vaccine in India.
Mohapatra JK; Hemadri D; Rao TV; Sreenivasa BP; Subramaniam S; Sanyal A; Periyasamy TR; Singh NK; Pattnaik B; Venkataramanan R
Vet Microbiol; 2008 Sep; 131(1-2):65-72. PubMed ID: 18394827
[TBL] [Abstract][Full Text] [Related]
15. Cedivac-FMD can be used according to a marker vaccine principle.
Chénard G; Selman P; Dekker A
Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508
[TBL] [Abstract][Full Text] [Related]
16. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV
Vaccine; 2006 Apr; 24(16):3184-90. PubMed ID: 16488060
[TBL] [Abstract][Full Text] [Related]
17. Characterization of foot-and-mouth disease virus from outbreaks in Ecuador during 2009-2010 and cross-protection studies with the vaccine strain in use in the region.
Maradei E; Perez Beascoechea C; Malirat V; Salgado G; Seki C; Pedemonte A; Bonastre P; D'Aloia R; La Torre JL; Mattion N; Rodríguez Toledo J; Bergmann IE
Vaccine; 2011 Oct; 29(46):8230-40. PubMed ID: 21911020
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs.
Eblé PL; de Bruin MG; Bouma A; van Hemert-Kluitenberg F; Dekker A
Vaccine; 2006 Feb; 24(9):1274-81. PubMed ID: 16289709
[TBL] [Abstract][Full Text] [Related]
19. FMD vaccine matching: Inter laboratory study for improved understanding of r
Willems T; De Vleeschauwer A; Perez-Filgueira M; Li Y; Ludi A; Lefebvre D; Wilsden G; Statham B; Haas B; Mattion N; Robiolo B; Beascoechea Perez C; Maradei E; Smitsaart E; La Torre J; De Clercq K
J Virol Methods; 2020 Feb; 276():113786. PubMed ID: 31765721
[TBL] [Abstract][Full Text] [Related]
20. Human adenovirus-vectored foot-and-mouth disease vaccines: establishment of a vaccine product profile through in vitro testing.
Brake DA; McIlhaney M; Miller T; Christianson K; Keene A; Lohnas G; Purcell C; Neilan J; Schutta C; Barrera J; Burrage T; Brough DE; Butman BT
Dev Biol (Basel); 2012; 134():123-33. PubMed ID: 22888605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
